SCYNEXIS

SCYNEXIS Gross Profit

The Gross Profit of SCYNEXIS (SCYX) as of Oct 27, 2026 is 20.60 M USD. In the previous year, Gross Profit was 3.75 M USD — a change of 449.95% (higher).

Gross Profit

20.60 MUSD

YoY

449.95%

Last updated:

Gross Profit of SCYNEXIS is 2025 20.60 M USD. Gross Profit of SCYNEXIS was 2024 3.75 M USD. It decreases by 449.95% higher compared to the previous year.

The SCYNEXIS Gross Profit history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Profit
Date
Gross Profit
Jan 1, 2018
257,000.00 USD
Jan 1, 2019
121,000.00 USD
Jan 1, 2020
-303,000.00 USD
Jan 1, 2021
12.85 M USD
Jan 1, 2022
4.46 M USD
Jan 1, 2023
124.52 M USD
Jan 1, 2024
3.75 M USD
Jan 1, 2025
20.60 M USD
The SCYNEXIS Gross Profit history
YEARGross ProfitYoY
20.60 MUSD+449.95%
3.75 MUSD-96.99%
124.52 MUSD+2,689.98%
4.46 MUSD-65.27%
12.85 MUSD-4,341.25%
-303,000.00USD-350.41%
121,000.00USD-52.92%
257,000.00USD0.00%
257,000.00USD0.00%
257,000.00USD0.00%
257,000.00USD-101.81%
-14.19 MUSD-2,670.65%
552,000.00USD-77.68%
2.47 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SCYNEXIS Revenue

SCYNEXIS Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
3.75 M USD
-37.12 M USD
-21.29 M USD
Jan 1, 2025
20.60 M USD
-16.07 M USD
-8.61 M USD
Jan 1, 2026 (e)
619,500.00 USD
-3.13 M USD
-122.13 M USD
Jan 1, 2027 (e)
6.68 M USD
-28.40 M USD
-97.16 M USD
Jan 1, 2028 (e)
14.68 M USD
-19.80 M USD
-12.56 M USD
Jan 1, 2029 (e)
14.31 M USD
-23.93 M USD
-15.41 M USD
Jan 1, 2030 (e)
40.45 M USD
-2.66 M USD
32.11 M USD
Jan 1, 2031 (e)
67.49 M USD
0.00 USD
0.00 USD

SCYNEXIS Margins

SCYNEXIS stock margins

The SCYNEXIS margin analysis displays the gross margin, EBIT margin, as well as the profit margin of SCYNEXIS. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for SCYNEXIS.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
100.00 %
-990.84 %
-568.29 %
Jan 1, 2025
100.00 %
-78.03 %
-41.79 %
Jan 1, 2026 (e)
100.00 %
-505.14 %
-19,714.72 %
Jan 1, 2027 (e)
100.00 %
-425.30 %
-1,455.08 %
Jan 1, 2028 (e)
100.00 %
-134.84 %
-85.51 %
Jan 1, 2029 (e)
100.00 %
-167.17 %
-107.68 %
Jan 1, 2030 (e)
100.00 %
-6.57 %
79.37 %
Jan 1, 2031 (e)
100.00 %
0.00 %
0.00 %

SCYNEXIS Stock analysis

What does SCYNEXIS do? SCYNEXIS Inc is a biopharmaceutical company that focuses on the discovery and development of novel therapeutics for serious infectious diseases and cancer. The company was founded in 2000 and is headquartered in New Jersey, USA. SCYNEXIS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCYNEXIS stock

Gross Profit of SCYNEXIS is 20.60 M USD in 2025.

Gross Profit of SCYNEXIS changed from 3.75 M USD to 20.60 M USD, representing a 449.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit SCYNEXIS since 2006 – with annual values, charts, and detailed analysis.

Gross Profit is the revenue remaining after deducting the cost of goods sold. It shows how efficiently a company uses its resources to produce goods or services.

Gross Profit's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Gross Profit's SCYNEXIS historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — SCYNEXIS

All Key Metrics — SCYNEXIS